Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
17 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Outlook Therapeutics appointed Greg DiPasquale chief commercial officer. He will lead commercialization efforts for LYTENAVA as the company prepares a U.S. launch before the end of 2026.
Dow Jones’ 5 p.m. ET roundup highlights a series of company updates, including Microsoft’s new Xbox unit, PepsiCo’s outlook cut, Viatris’ planned Pacira BioSciences acquisition and Samsung’s profit outlook.
Dow Jones Newswires listed a series of corporate and regulatory headlines, including Microsoft, PepsiCo, Devon Energy, Viatris and Samsung. The package also included legal, production and deal updates across several companies.
PepsiCo cut its full-year earnings outlook as inflation, higher advertising costs and continued weakness in North America weighed on results. The company said it is working to reduce expenses and revive sales.
NVIDIA said it will commit $1 billion over five years to support U.S. science, including quantum computing, healthcare and energy security. The company said the effort is part of its collaboration with the Genesis Mission and U.S. research institutions.
FibroBiologics said it filed a U.S. patent application for a cell-based technology designed to continuously produce GLP-1 and other therapeutic peptides inside the body. The company said the approach is intended as an alternative to repeated injections or pills.
Dow Jones Newswires published a recap of its private markets coverage from the last trading day. The package lists several deal, financing, product and legal headlines.
On Thursday, Ligand Pharmaceuticals (NASDAQ: LGND ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. The full earnings call is available at Summary Full Transcri
Stoke Therapeutics announced two presentations of data for STK-002, an investigational medicine targeting Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting. The company also provided an update on its Phase 1 OSPREY study, with initial safety and efficacy data an
Formycon AG is incorporating AI and digital technologies into its biosimilar development processes, aiming to optimize workflows and create sustainable value. The company is implementing PhlexTMF Enterprise, an electronic trial master file solution with AI-assisted capabilities, and an AI-powered software for analyzing
The EPCORE DLBCL-2 trial showed that epcoritamab combined with R-CHOP reduced the risk of disease progression or death by 51% compared to R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma patients.
The company said second-quarter revenue rose 30.1% year over year to 1.39 billion RMB, while net income increased 35.6% to 413.2 million RMB. Yuanbao also said cash reserves totaled 5.16 billion RMB and it had repurchased about 114,000 ADS for US$1.6 million as of Aug. 31, 2026.
Millions of Medicare beneficiaries will gain access to obesity drugs for the first time starting Wednesday under CMS’ temporary Bridge program, a federal initiative designed to expand GLP-1 obesity drug coverage for eligible seniors at a $50 monthly copay. The program marks a major shift in Medicare coverage. While Med
Medici Daniel John submits SEC filing
Revolution Medicines submits filing to SEC, disclosure pending review
BeOne Medicines Ltd submits filing to SEC, disclosure pending review
Revolution Medicines submits filing to SEC, disclosure pending